Eternygen is a startup based in Germany, most recent round Acquired, 1 tracked investor.
Eternygen is a startup founded in 2012 based in Germany. Eternygen has been acquired. Brouky records 1 investor associated with the company.
Eternygen was a German biotech company focused on discovering and developing novel therapeutics for metabolic diseases, particularly targeting SMCT1 for non-alcoholic steatohepatitis (NASH). The company was acquired by Novo Nordisk in 2019.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.